- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Lambert-Eaton myasthenic syndrome
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 436KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 70KB)
Amifampridine – March 2022
Amifampridine: Tablet 10 mg; Ruzurgi®
Last updated
1 July 2022